Biomerica to present at the ROTH conference on March 16, 2016
Irvine, Calif. -- March 10, 2016 --
Biomerica Inc. (OTCBB: BMRA) ) today announced that Zackary Irani, Chief Executive Officer of Biomerica, will present a business update about its IBS (Irritable Bowel Syndrome) product at the Roth Capital Partners 28th Annual Growth Stock Conference on Wednesday, March 16, 2016 at 10:30 am PT, at the Ritz-Carlton Hotel, Dana Point, CA.
To access the live audio webcast of the ROTH presentation, please log on through a link located in the Investors section of Biomerica's website at www.biomerica.com, under the News tab. A replay of the webcast will be available one hour after the conclusion of the live event.
About Biomerica (OTCBB: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. The Company's products are designed to enhance the health and well being of people, while reducing total healthcare costs. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by Biomerica) contains statements that are forward-looking; such as statements relating to intended launch dates, sales potential, significant benefits, market size, prospects, new products, favorable outlook, new distributors, expansion, increases in productivity and margins, expected orders, leading market positions, anticipated future sales or production volume of the Company, the launch or success of product and new product offerings. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future, and accordingly, such results may differ materially from those expressed in any forward-looking statements made by or on behalf of Biomerica. The potential risks and uncertainties include, among others, fluctuations in the Company's operating results due to its business model and expansion plans, downturns in international and or national economies, the Company's ability to raise additional capital, the competitive environment in which the Company will be competing, and the Company's dependence on strategic relationships. The Company is under no obligation to update any forward-looking statements after the date of this release.